Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: Inhaled corticposteroids (ICS)Drug: Second Asthma Controller Medication
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT02099656
- Locations
- 🇺🇸
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, United States
🇺🇸Pen Memory Center, Philadelphia, Pennsylvania, United States
🇬🇧St Mary's Hospital, London, United Kingdom
An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants
- Conditions
- Basal Cell Carcinoma
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT02100111
- Locations
- 🇮🇹
Irccs Crob, Rionero in Vulture, Basilicata, Italy
🇫🇷Hôpital St Jacques de Besançon; (Dermatology), Besançon, France
🇫🇷Hopital Saint Andre CHU De Bordeaux; Dermatologie, Bordeaux, France
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT02098967
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇦University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇺🇸University of Colorado, Aurora, Colorado, United States
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT02097745
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
- Conditions
- Locally Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 84
- Registration Number
- NCT02097810
- Locations
- 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 201
- Registration Number
- NCT02093000
- Locations
- 🇭🇺
Veszprem Megyei Onkormanyzat Tudogyogyintezet, Farkasgyepu, Hungary
🇭🇺University of Pecs; 1St Department of Medicine, Pecs, Hungary
🇭🇺Matrai Gyogyintezet, Matrahaza, Hungary
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 465
- Registration Number
- NCT02093026
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
- Conditions
- Heart Transplantation
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT02091414
A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Drug: Cyclophosphamide, Maintenance PhaseDrug: Cyclophosphamide, Induction Phase
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT02081183
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT02080884
- Locations
- 🇭🇺
Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary
🇭🇺Semmelweis University, First Dept of Medicine, Budapest, Hungary
🇭🇺National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary